Treatment outcomes of gestational choriocarcinoma before and after EMA/CO introduction in Mongolia: a 15-year retrospective cohort study - Top-Institutions - MDSpire

Treatment outcomes of gestational choriocarcinoma before and after EMA/CO introduction in Mongolia: a 15-year retrospective cohort study

  • By

  • Ulziijargal Sukhbat

  • Gandolgor Batsuuri

  • Eiko Yamamoto

  • Terkhen Turbat

  • Oyujin Ulziibaatar

  • Baatarkhuu Oidov

  • Ita Daryanti Saragih

  • Namuun Ganzul

  • Yen-Liang Liu

  • Jargalsaikhan Badarch

  • July 17, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Charing Cross Gestational Trophoblastic Disease Centre, Imperial College Healthcare NHS Trust
    Charing Cross Gestational Trophoblastic Disease Centre, Imperial College Healthcare NHS Trust

    London, United Kingdom

    Key Differentiators

    • Gestational Trophoblastic Disease
    • Oncology

  • #2

    Dana-Farber/Brigham and Women’s Cancer Center
    Dana-Farber/Brigham and Women’s Cancer Center

    Boston, Massachusetts

    Key Differentiators

    • Gestational Trophoblastic Disease
    • Oncology

  • #3

    British Columbia Cancer Agency
    British Columbia Cancer Agency

    Vancouver, British Columbia

    Key Differentiators

    • Oncology

  • #4

    Seoul National University Bundang Hospital
    Seoul National University Bundang Hospital

    Seongnam, South Korea

    Key Differentiators

    • Oncology

  • #5

    Peking University People’s Hospital
    Peking University People’s Hospital

    Beijing, China

    Key Differentiators

    • Oncology

Original Source(s)

Treatment outcomes of gestational choriocarcinoma before and after EMA/CO introduction in Mongolia: a 15-year retrospective cohort study

  • by Ulziijargal Sukhbat, Gandolgor Batsuuri, Eiko Yamamoto, Terkhen Turbat, Oyujin Ulziibaatar, Baatarkhuu Oidov, Ita Daryanti Saragih, Namuun Ganzul, Yen-Liang Liu, Jargalsaikhan Badarch

  • July 17, 2026

Related Content

Cellular responses to targeted radionuclide therapy: rethinking radiobiology under continuous low dose rates

Correction: Crosstalk between abnormal TSHR signaling activation and PTEN/PI3K in the dedifferentiation of thyroid cancer cells

The dual role of parasites and parasite-derived products in cancer biology: a systematic review of in vitro and in vivo evidence